According to the Tufts Center for the Study of Drug Development, the number of investigational drugs targeting cancer has nearly quadrupled since 2000, to 1,489 trials in 2021, up from 421 two decades earlier. Life sciences companies focused on oncology are increasingly shifting toward precision medicine, but as they do so, it becomes harder to find clinical trial participants that fit the selective criteria. But once you do find participants, it’s critical to retain them.
In this webinar, we’ll discuss a new framework for retaining and engaging participants in long-term oncology studies, including:
- How to reduce participant friction
- How to engage participants through motivational intervals
- A better way to ensure medication adherence
- And how to communicate with participants and investigate possible adverse events